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Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibi-
tors are frequently used in combination for the treatment of type 2 diabetes mellitus (T2DM).
We examined the efficacy and safety of teneligliptin (a DPP-4 inhibitor) added to canagliflozin
(an SGLT2 inhibitor) monotherapy in Japanese patients with poorly controlled T2DM as part of
the development of a fixed-dose combination of teneligliptin and canagliflozin.
Japanese patients treated with canagliflozin (100 mg) for ≥12 weeks were randomized to
receive add-on teneligliptin (20 mg; C + T group) or placebo (C + P group) for 24 weeks. The
primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to Week 24. The
between-group differences in reductions from baseline to Week 24 were significantly greater
in the C + T group for HbA1c (−0.94%; P < .001). The incidence of adverse events was similar
in both groups (55.8% and 49.4% in the C + T and C + P groups, respectively). No episodes of
hypoglycaemia were reported. Teneligliptin added to ongoing canagliflozin monotherapy
improved glycaemic control and was well tolerated in Japanese patients with inadequately con-
trolled T2DM.
KEYWORDS
canagliflozin, dipeptidyl peptidase-4 inhibitor, sodium glucose co-transporter 2 inhibitor,
teneligliptin, type 2 diabetes mellitus
1 | INTRODUCTION
By inhibiting the degradation of glucagon-like peptide-1, dipeptidyl
peptidase-4 (DPP-4) inhibitors promote insulin secretion and sup-
press glucagon secretion. Because the mode of action is dependent
on the glucose concentration, DPP-4 inhibitors have a low risk of
causing hypoglycaemia.1 Sodium glucose co-transporter 2 (SGLT2)
inhibitors reduce urinary glucose reabsorption by inhibiting SGLT2,
lower plasma glucose in an insulin-independent manner and help to
alleviate glucose toxicity. They are also expected to improve insulin
resistance by alleviating glucose toxicity and decreasing body
weight.2,3 The independent mechanisms of action of these drugs and
the low risk of hypoglycaemia provide support for combination ther-
apy as a therapeutic option. Indeed, prior studies have demonstrated
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that combination therapy with an SGLT2 inhibitor and a DPP-4 inhib-
itor was effective and well tolerated.4–8
Consequently, fixed-dose combinations of a DPP-4 inhibitor and
an SGLT2 inhibitor are anticipated, and 2 fixed-dose combination
drugs of a DPP-4 inhibitor and an SGLT2 inhibitor, linagliptin/empa-
gliflozin and saxagliptin/dapagliflozin, have been launched in the USA
and Europe, respectively.8–10 No fixed-dose combinations of a DPP-4
inhibitor and an SGLT2 inhibitor have been approved in Japan.
In this context, the development of a fixed-dose combination of
teneligliptin, a DPP-4 inhibitor, and canagliflozin, an SGLT2 inhibitor,
has proceeded. A study examining the efficacy and safety of adding
canagliflozin to ongoing teneligliptin therapy in Japanese patients has
also been conducted (NCT02354235, NCT02220907), and the results
have been reported previously.11,12 In this study, we examined the
efficacy of teneligliptin added to canagliflozin monotherapy in Japa-
nese patients with poorly controlled T2DM as part of the develop-
ment programme. This is the first clinical trial evaluating the efficacy
and safety of adding a DPP-4 inhibitor to ongoing SGLT2 inhibitor
treatment in Japanese T2DM patients. Therefore, this trial provides
important information because there are differences in the pathology
of T2DM between Japanese and Caucasian patients.13
2 | METHODS
Details of the patient inclusion/exclusion criteria, secondary efficacy
endpoints and statistical analyses are provided in Appendix S1
(Methods). In brief, Japanese patients with T2DM and inadequate
glycaemic control despite canagliflozin monotherapy in conjunction
with diet and exercise therapy were eligible, provided they had
undergone canagliflozin monotherapy for ≥8 weeks before the run-in
period.
2.1 | Ethics
This trial complied with the Declaration of Helsinki, the Japanese Law
for Ensuring the Quality, Efficacy, and Safety of Drugs and Medical
Devices, Good Clinical Practice, and the approved study protocol.
The procedures were approved by institutional review boards at all
participating institutions, which are listed in Appendix S1. The trial
was registered at ClinicalTrials.gov (NCT02354222).
2.2 | Study design and treatments
The study comprised a 4-week run-in period, a 24-week double-blind
treatment period, and a 2-week post-treatment observation period
(Figure S1). All patients received canagliflozin at a dose of 100 mg
(the approved dose in Japan) once daily before breakfast during the
run-in period, treatment period and post-treatment observation
period. At the start of the treatment period, patients were rando-
mized in a 1:1 manner to receive placebo (C + P group) or teneliglip-
tin (C + T group) at a dose of 20 mg once daily before breakfast.
Randomization was performed using the permuted block method.
Diet and exercise therapy was to continue unchanged throughout the
trial.
2.3 | Primary efficacy and safety endpoints
The primary efficacy endpoint was the change in HbA1c from base-
line to the end of the treatment period. The safety of C + T and
C + P was assessed in terms of adverse events (AEs), hypoglycaemia,
laboratory variables (haematology, blood biochemistry and urinalysis),
electrocardiography and vital signs. AEs were evaluated in terms of
their seriousness and relationship to the study drugs. AEs and drug-
related AEs were classified according to the System Organ Class and
Preferred Term using the MedDRA version 18.1J.
3 | RESULTS
3.1 | Patient disposition and baseline characteristics
A total of 213 patients were initially enrolled, of whom 59 discontin-
ued before the treatment period (Figure S2); therefore, 154 patients
were randomized, with 77 patients per group. Patient characteristics
are shown in Table S1, Appendix S1.
3.2 | Efficacy variables
The primary endpoint, the LS mean  SE (baseline value as covariate)
change in HbA1c from baseline to Week 24 (LOCF) was
0.00%  0.08% and −0.94%  0.08% in the C + P and C + T groups,
respectively, with a significant between-group difference of
−0.94%  0.11% (P < .001, two-sided ANCOVA as specified in the
protocol) (Table S2, Appendix S1). As illustrated in Figure 1, HbA1c
started to decrease within 4 weeks of treatment in the C + T group
and continued to decrease through to Week 12, and the reduction
was sustained until the end of treatment. By contrast, HbA1c
remained broadly unchanged in the C + P group. Significantly greater
FIGURE 1 Changes in HbA1c from baseline to each visit during the
24-week treatment period, and at the last observation carried
forward. Values are expressed as the least squares mean  standard
error. The least squares mean was determined by analysis of
covariance with treatment group as a fixed factor and the baseline
value as a covariate. *P < .001 for the C + T group vs C + P group at
all time points. C + P, canagliflozin plus placebo; C + T, canagliflozin
plus teneligliptin; HbA1c, glycated haemoglobin; LOCF, last
observation carried forward; LS mean, least squares mean
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proportions of patients in the C + T group than in the C + P group
achieved HbA1c <7.0% (50.00% vs 8.11%, respectively; P < .001) or
<8.0% (75.76% vs 18.42%, respectively; P < .001, 2-sided Fisher’s
exact test as specified in the protocol) at Week 24 (LOCF).
Table S2 (Appendix S1) shows the changes in other efficacy end-
points from baseline to Week 24 (LOCF). Supporting the change in
HbA1c, the reduction in FPG was significantly greater in the C + T
group, with a between-group difference of −15.6  3.9 mg/dL
(LS mean  SE, P < .001, two-sided ANCOVA [baseline value as cov-
ariate] as specified in the protocol). The absolute and percent
changes in body weight were 0.11  0.20 kg and 0.09%  0.29%,
respectively, in the C + T group vs −0.98  0.20 kg and
−1.34%  0.29%, respectively, in the C + P group. The between-
group differences in changes in body weight were 1.09  0.29 kg
and 1.43%  0.41% (both P < .001), respectively. Additional efficacy
results and the results of a mixed-meal tolerance test are included in
Appendix S1 (Results).
3.3 | Safety
Table 1 shows the incidence of AEs, including AEs of special interest
in both groups. AEs and drug-related AEs occurred in 49.4% and
14.3% of patients, respectively, in the C + P group and in 55.8% and
6.5% of patients, respectively, in the C + T group. Serious AEs
occurred in 2.6% and 1.3% of patients in the C + P and C + T groups,
respectively. There were no serious drug-related AEs in either group.
AEs led to discontinuation and drug-related AEs led to discontinua-
tion in 3.9% and 1.3% of patients, respectively, in the C + P group.
There were no AEs leading to treatment discontinuation in the C + T
group. In terms of AEs of special interest, there were no episodes of
hypoglycaemia in either group. Gastrointestinal disorders (11.7% vs
7.8%) and skin and subcutaneous tissue disorders (10.4% vs 5.2%)
were more common in the C + T group than in the C + P group.
Malignant neoplasms occurred in 2.6% of patients in the C + P group
and in no patients in the C + T group. Other AEs of clinical relevance
occurred in ≤2 patients in each group.
4 | DISCUSSION
This randomized, placebo-controlled, double-blind, multicentre trial
examined the efficacy and safety of teneligliptin or placebo added to
canagliflozin therapy for 24 weeks in Japanese patients with inade-
quately controlled T2DM. Teneligliptin was associated with signifi-
cant improvements in glycaemic control, including HbA1c, FPG and
postprandial plasma glucose, compared with placebo. Moreover,
greater proportions of patients in the C + T group achieved HbA1c
<7.0% or <8.0%. These improvements were consistent with those
observed in earlier clinical trials in which teneligliptin was added to
oral hypoglycaemic drugs other than SGLT2 inhibitors.14–16 In fasting
conditions, the fasting proinsulin/C-peptide ratio was reduced and
HOMA2-%B was increased in the C + T group compared with the
C + P group. In addition, in mixed-meal tolerance tests, there were
reductions in the changes from baseline in postprandial plasma glu-
cose, as well as increases in the change from baseline in C-peptide
AUC0-2h and the C-peptide AUC0-2hours/plasma glucose AUC0-2hours
in the C + T group compared with the C + P group.
These findings seem reasonable considering the mechanism of
action of DPP-4 inhibitors, which promote insulin secretion in a glu-
cose concentration-dependent manner.1 Taken together, these
results support our hypothesis that teneligliptin added to ongoing
canagliflozin therapy is beneficial in terms of improving glycaemic
control in patients with inadequately controlled T2DM, because of
their complementary but independent mechanisms of action.
Additionally, the use of canagliflozin and teneligliptin in combina-
tion is considered to have the following benefits. First, the attenua-
tion of β-cell burden by the SGLT2 inhibitor may lead to enhanced
incretin-stimulated insulin secretion. Second, because canagliflozin
increases total GLP-1 after meals,17 teneligliptin add-on therapy may
increase the level of active GLP-1.
In this trial, the change in body weight from baseline to Week
24 was −0.98 kg in the C + P group and 0.11 kg in the C + T group.
The change in urinary glucose/creatinine ratio from baseline was
lower in the C + T group compared with the C + P group, probably
because of the glucose-lowering effect of teneligliptin. This result
suggests that calorie loss through glucose excretion was lower in the
C + T group than in the C + P group throughout the treatment
period. Furthermore, some meta-analyses and clinical trials of teneli-
gliptin have reported that DPP-4 inhibitors negligibly increase body
weight, probably as a result of enhanced insulin-stimulated glucose
uptake.15,16,18–20
The present trial also examined the safety of teneligliptin added
to ongoing canagliflozin therapy. Of note, there were no serious
TABLE 1 Adverse events
C + P C + T
n (%) n (%)
AEs 38 (49.4) 43 (55.8)
Drug-related AEs 11 (14.3) 5 (6.5)
Serious AEs 2 (2.6) 1 (1.3)
Serious drug-related AEs 0 (0.0) 0 (0.0)
AEs leading to discontinuation 3 (3.9) 0 (0.0)
Drug-related AEs leading to
discontinuation
1 (1.3) 0 (0.0)
AEs of special interest
Hypoglycaemia 0 (0.0) 0 (0.0)
Osmotic diuresis 1 (1.3) 1 (1.3)
Volume depletion 0 (0.0) 1 (1.3)
Vulvovaginal candidiasis 1 (5.3)a 0 (0.0)
Urinary tract infection 1 (1.3) 0 (0.0)
Blood ketone bodies increased 2 (2.6) 1 (1.3)
Hepatic function impairment 2 (2.6) 2 (2.6)
Skin and subcutaneous tissue
disorders
4 (5.2) 8 (10.4)
Cardiovascular-related events 0 (0.0) 1 (1.3)
Malignant neoplasm 2 (2.6) 0 (0.0)
Gastrointestinal disorders 6 (7.8) 9 (11.7)
Abbreviations: C + P, canagliflozin plus placebo; C + T, canagliflozin plus
teneligliptin; AE, adverse event.
a In females only (n = 19).
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drug-related AEs or deaths. Moreover, no episodes of hypoglycaemia
were detected. AEs related to osmotic diuresis, volume depletion,
increased serum ketone bodies, hepatic function impairment, skin dis-
orders, cardiovascular disorders and gastrointestinal disorders were
observed in the C + T group. Although skin disorders and gastrointes-
tinal disorders were slightly more frequent in the C + T group, only
one skin disorder (eczema) and one gastrointestinal disorder (consti-
pation) were considered to be drug-related in the C + T group. These
classes of AEs have already been reported for teneligliptin or canagli-
flozin, and there were no additional safety concerns. Overall, these
findings suggest that teneligliptin added to canagliflozin therapy is
likely to be well tolerated in clinical practice.
We previously reported that canagliflozin added to teneligliptin
monotherapy in Japanese patients with poorly controlled T2DM was
effective and well tolerated.11,12 Taken together with the results of
the present trial, this suggests that the fixed-dose combination of
teneligliptin and canagliflozin may be a beneficial treatment option.
Some limitations of this study warrant mention. In particular, we
enrolled only Japanese patients. However, data on the use of this
drug combination in Japanese patients are important, particularly
when we consider the differences in pathophysiology between Japa-
nese and non-Japanese patients.13 Longer studies may be needed to
verify the current findings obtained over 24 weeks.
In conclusion, this trial showed that teneligliptin added to ongoing
canagliflozin therapy was effective in terms of improving glycaemic
control and was well tolerated in Japanese patients with inadequately
controlled T2DM.
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